Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Go back to Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule| (NASDAQ: HELP) | Delayed: 12.37 -1.65 (11.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.02 | 52 Week High | $ | |||
| Open | $15.15 | 52 Week Low | $ | |||
| Day High | $15.15 | P/E | N/A | |||
| Day Low | $12.10 | EPS | $ | |||
| Volume | 5,661,925 | |||||
